Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy (Q45254298)

From Wikidata
Jump to navigation Jump to search
scientific article published on January 1, 1992
edit
Language Label Description Also known as
English
Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy
scientific article published on January 1, 1992

    Statements

    Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy (English)
    Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy (English)
    1 January 1992
    50-55

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit